Apellis Pharmaceuticals, Inc. (APLS) Misses Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Apellis Pharmaceuticals, Inc. (APLS) Misses Q2 EPS by 5c

Stifel Reiterates Buy Rating on Apellis Pharmaceuticals (APLS), 'we think the entire package presents a relatively convincing picture'

August 9, 2022 4:02 AM EDT

Stifel analyst Annabel Samimy reiterated a Buy rating and $60.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).

The analyst comments "While we await a seminal decision on pegcetacoplan in GA (11/26/22), APLS continues to execute on the Empaveli/PNH commercial launch, with sales reaching $16.3mn/Cons.... More

Cowen Reiterates Outperform Rating on Apellis Pharmaceuticals (APLS), 'We Remain Optimistic For Pegcetacoplan Approval'

August 9, 2022 4:01 AM EDT

Cowen analyst Phil Nadeau reiterated an Outperform rating and $70.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).

The analyst comments "We continue to view the acceptance, granting of Priority Review for the sNDA for pegcetacoplan in GA and the fact that the... More

Roth Capital Reiterates Sell Rating on Apellis Pharmaceuticals (APLS), Street Low $40 PT

August 9, 2022 3:58 AM EDT

Roth Capital analyst Elemer Piros reiterated a Sell rating and $40.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).

The analyst comments "We arrive at our 12-month price target of $40/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from pegcetacoplan for treatment PNH... More